BRIEF published on 06/30/2025 at 14:05, 5 months 4 days ago Promising Phase 1b Results for invIOs's APN401 Cell Therapy in Advanced Tumors Cell Therapy Phase 1b Trial InvIOs GmbH APN401 Advanced Tumors
BRIEF published on 06/30/2025 at 14:05, 5 months 4 days ago Résultats prometteurs de phase 1b pour la thérapie cellulaire APN401 d'invIOs dans les tumeurs avancées Thérapie Cellulaire InvIOs GmbH APN401 Essai De Phase 1b Tumeurs Avancées
PRESS RELEASE published on 06/30/2025 at 14:00, 5 months 4 days ago invIOs reports promising Phase 1b results for cell therapy APN401 in advanced solid tumors invIOs reports successful Phase 1b trial results for APN401 cell therapy in advanced solid tumors, showing safety and efficacy in late-stage cancer patients Solid Tumors Cell Therapy Phase 1b Trial InvIOs APN401
BRIEF published on 12/16/2024 at 15:05, 11 months 19 days ago InvIOs to Highlight Oncology Pipeline Progress at JP Morgan Week 2025 Oncology Cancer Research Cell Therapy Glioblastoma InvIOs GmbH
BRIEF published on 12/16/2024 at 15:05, 11 months 19 days ago InvIOs mettra en avant les progrès du pipeline oncologique lors de la JP Morgan Week 2025 Thérapie Cellulaire Oncologie Glioblastome Recherche Sur Le Cancer InvIOs GmbH
PRESS RELEASE published on 12/16/2024 at 15:00, 11 months 19 days ago invIOs to present progress across oncology pipeline during JP Morgan Week 2025 invIOs GmbH to present progress in oncology pipeline at JP Morgan Week 2025, including updates on glioblastoma treatments INV501 and INV441 in collaboration with DFCI Oncology Pipeline InvIOs GmbH JP Morgan Week 2025 Glioblastoma Treatments DFCI Collaboration
BRIEF published on 10/15/2024 at 10:35, 1 year 1 month ago InvIOs Secures €8.2 Million Series A Funding for Immuno-oncology Innovations Biotechnology Fundraising Clinical Trials Immuno-oncology InvIOs GmbH
BRIEF published on 10/15/2024 at 10:35, 1 year 1 month ago InvIOS obtient un financement de série A de 8,2 millions d'euros pour des innovations en immuno-oncologie Biotechnologie Essais Cliniques Immuno-oncologie Collecte De Fonds InvIOs GmbH
PRESS RELEASE published on 10/15/2024 at 10:30, 1 year 1 month ago invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology invIOs GmbH raises €8.2 million in Series A funding to advance immuno-oncology pipeline progress through 2025, collaborating with Dana-Farber Cancer Institute Series A Funding Immuno-oncology Pipeline Progress InvIOs Dana-Farber Cancer Institute
BRIEF published on 07/17/2024 at 10:05, 1 year 4 months ago InvIOs Selects INV501 Lead Candidate for IND-Enabling Studies in Glioblastoma and Melanoma Cancer Therapy Melanoma Preclinical Studies INV501 Glioblastoma
Published on 12/05/2025 at 02:35, 4 hours 2 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 37 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 32 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 37 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 7 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 46 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 12 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 22 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 27 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 23 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
